Ineffective treatment of lung infections with roxithromycin may be due to failure of the drug to cover the pathogen, drug resistance, and insufficient drug regimen. Lung infections are caused by bacterial, viral, fungal, atypical pathogens and other infections as well as physical and chemical factors. Roxithromycin belongs to macrolide antibiotics, mainly used for the treatment of lung infections caused by common bacteria or atypical pathogens such as chlamydia, mycoplasma and other infections. The use of roxithromycin is not effective in controlling the condition, which may be due to the short duration of the medication, the drug is resistant to the current pathogen, or the current pathogen of the infection may be viral, fungal and so on. At this time, it is recommended to consult a doctor in a timely manner, by a professional physician according to the results of sputum culture and drug sensitivity test, adjust the drug program, if the bacteria are resistant to roxithromycin, according to the drug sensitivity test to replace the sensitive antibiotics for treatment, such as fungal infections can be selected fluconazole, voriconazole and other drugs for treatment. The above drugs need to be standardized and rationally applied under the guidance of professional physicians and pharmacists.